Skip to main content
. Author manuscript; available in PMC: 2021 Apr 16.
Published in final edited form as: Br J Ophthalmol. 2020 Jun 12;105(4):549–554. doi: 10.1136/bjophthalmol-2020-315836

Figure 2.

Figure 2

Mean VA (left) and change from baseline in VA (right) during the first 3 years for 215 all treatment groups. anti-VEGF, anti-vascular endothelial growth factor; VA, visualacuity.